Story perspectives

FDA-Approved Fendiline Shows Promise Against Antibiotic Resistance

6/11/2025

37 6

Summary

Story summary

A groundbreaking study from Emory University uncovers that fendiline, a calcium channel blocker, holds promise against the formidable antibiotic-resistant Acinetobacter baumannii, particularly threatening immunocompromised patients in hospitals. This FDA-approved medication could revolutionize treatment by targeting a weakness in resistant bacteria while safeguarding healthy gut flora, highlighting an urgent need for improved therapies in the fight against stubborn infections.

1 of 1

Story summary

A groundbreaking study from Emory University uncovers that fendiline, a calcium channel blocker, holds promise against the formidable antibiotic-resistant Acinetobacter baumannii, particularly threatening immunocompromised patients in hospitals. This FDA-approved medication could revolutionize treatment by targeting a weakness in resistant bacteria while safeguarding healthy gut flora, highlighting an urgent need for improved therapies in the fight against stubborn infections.